Neurologists have found in a recent study that common drugs to treat multiple sclerosis lead to modest health benefits but very high costs, according to a news release from Kirkland, Wash.-based ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

New MS treatments target myelin repair, neuroprotection, and CNS-resident immune cells, offering hope for progressive forms of the disease. Bruton tyrosine kinase inhibitors (BTKis) like tolebrutinib ...

Two novel sub-types of multiple sclerosis (MS) have been identified, a discovery potentially paving the way for new treatments. Researchers employed artificial intelligence (AI) to assess brain scans ...

BTK inhibitor implementation for MS treatment is explored. Ryan Haumschild, PharmD, MS, MBA: Now if we could, let’s discuss the emerging role of Bruton tyrosine kinase inhibitors [BTKis] in multiple ...

"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...

Pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis (MS). CAMH-led pre-clinical studies using a small molecule drug have shown ...

Smoldering-associated worsening (SAW) of multiple sclerosis (MS) deserves a broader, more comprehensive approach to diagnosis, treatment, and research that goes beyond neurologists’ understanding of ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod. There are ...

Kessler Foundation research scientist John DeLuca, PhD, has published a significant clinical article in Journal of Neurology, shedding light on the elusive nature of fatigue in multiple sclerosis (MS) ...